Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Agile Therapeutics Q1 2024 Adj EPS $(0.63) Misses $(0.51) Estimate, Sales $5.72M Beat $3.75M Estimate

Author: Benzinga Newsdesk | May 15, 2024 04:43pm
Agile Therapeutics (NASDAQ:AGRX) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.51) by 23.53 percent. The company reported quarterly sales of $5.72 million which beat the analyst consensus estimate of $3.75 million by 52.35 percent. This is a 49.91 percent increase over sales of $3.81 million the same period last year.

Posted In: AGRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist